AFCAPS/TexCAPS acute coronary disease results - Relative risks (and 95% CIs) associated with lovastatin therapy, according to baseline lipid and C-reactive protein levels.

Data are from Table 2 in [36].
5 year risk (%), risk of an acute coronary event in the placebo arm group (in other words, this is a baseline risk for this population); A, any hsCRP; H, LDL or hsCRP higher than the median; L, LDL or hsCRP lower than the median.